In vivo drug-drug interaction studies--a survey of all new molecular entities approved from 1987 to 1997

Clin Pharmacol Ther. 2000 Sep;68(3):280-5. doi: 10.1067/mcp.2000.109366.


Ninety-eight new molecular entities applications approved between 1987 to 1991 (period I) and 193 applications for new molecular entities between 1992 to 1997 (period II) were surveyed for drug-drug interaction studies. In period I (used as a comparator), 32 applications contained drug-drug interaction studies for a total of 117 studies. In period II, 106 applications reported drug-drug interaction studies, and the number of studies per new molecular entity ranged from 0 to 15. Most studies (77%) were performed in healthy subjects, with 44% using crossover designs, 7% using parallel designs, and the remaining using fixed sequence designs. The most common dosing scheme for new molecular entities/interacting drug was multiple dose (47%), whereas single dose/multiple dose was used in 31% of studies, and single dose/single dose was used in 18% of studies. Of the 540 drug-drug interaction studies submitted in period II, 80 (15%) resulted in clinically significant labeling statements. Submissions for new molecular entities to the Center for Drug Evaluation and Research divisions most likely to include drug-drug interaction studies were neuropharmacology, cardiorenal, antiviral, and antiinfective drugs. Some drug classes such as oncology drug products and radioimaging products were least likely to include drug-drug interaction studies in their submissions. We conclude that the use of drug-drug interaction studies in the drug development process has increased between the two periods.

MeSH terms

  • Biopharmaceutics*
  • Clinical Trials as Topic
  • Cross-Over Studies
  • Databases, Factual
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Interactions*
  • Humans
  • United States
  • United States Food and Drug Administration